Jane Street Group LLC Has $2.89 Million Stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Jane Street Group LLC boosted its stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 122.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 765,475 shares of the company's stock after purchasing an additional 421,302 shares during the quarter. Jane Street Group LLC owned approximately 1.12% of Amylyx Pharmaceuticals worth $2,893,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Blue Trust Inc. grew its stake in shares of Amylyx Pharmaceuticals by 232.1% in the fourth quarter. Blue Trust Inc. now owns 6,987 shares of the company's stock worth $26,000 after purchasing an additional 4,883 shares in the last quarter. XTX Topco Ltd boosted its position in shares of Amylyx Pharmaceuticals by 12.0% in the 4th quarter. XTX Topco Ltd now owns 53,376 shares of the company's stock valued at $202,000 after purchasing an additional 5,704 shares during the period. Northern Trust Corp increased its position in shares of Amylyx Pharmaceuticals by 11.8% in the fourth quarter. Northern Trust Corp now owns 106,564 shares of the company's stock worth $403,000 after acquiring an additional 11,214 shares in the last quarter. Fox Run Management L.L.C. purchased a new position in Amylyx Pharmaceuticals during the 4th quarter worth approximately $45,000. Finally, Alpine Global Management LLC purchased a new position in shares of Amylyx Pharmaceuticals during the fourth quarter valued at $45,000. Institutional investors and hedge funds own 95.84% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on AMLX. HC Wainwright upped their price objective on shares of Amylyx Pharmaceuticals from $12.00 to $16.00 and gave the company a "buy" rating in a research note on Friday, May 9th. Leerink Partnrs raised Amylyx Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, May 6th. Mizuho upped their price target on Amylyx Pharmaceuticals from $7.00 to $8.00 and gave the stock an "outperform" rating in a report on Wednesday, May 14th. Finally, Leerink Partners raised shares of Amylyx Pharmaceuticals from a "market perform" rating to an "outperform" rating and upped their price objective for the company from $4.00 to $10.00 in a research report on Wednesday, May 7th. One analyst has rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $9.83.

Insider Transactions at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, CFO James M. Frates sold 10,896 shares of the firm's stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $3.47, for a total value of $37,809.12. Following the transaction, the chief financial officer now directly owns 290,988 shares of the company's stock, valued at approximately $1,009,728.36. This trade represents a 3.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bernhardt G. Zeiher acquired 10,000 shares of the firm's stock in a transaction that occurred on Thursday, March 20th. The shares were bought at an average cost of $3.70 per share, with a total value of $37,000.00. Following the completion of the purchase, the director now owns 10,000 shares of the company's stock, valued at $37,000. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 48,980 shares of company stock worth $168,627. Insiders own 11.70% of the company's stock.

Amylyx Pharmaceuticals Price Performance

Shares of AMLX traded up $0.52 during mid-day trading on Monday, reaching $5.36. The company had a trading volume of 1,996,877 shares, compared to its average volume of 1,220,233. The company has a market capitalization of $477.80 million, a P/E ratio of -1.40 and a beta of -0.60. Amylyx Pharmaceuticals, Inc. has a twelve month low of $1.58 and a twelve month high of $7.27. The company's 50-day moving average is $4.17 and its 200-day moving average is $4.19.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.03. As a group, equities analysts expect that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current fiscal year.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.